Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for LivaNova PLC (NASDAQ: LIVN), a global medical technology company headquartered in London and incorporated in England and Wales. As a foreign private issuer with securities listed in the United States, LivaNova files reports with the Securities and Exchange Commission that document material events, financial results, and corporate governance changes.
Among the filings available are Form 8‑K current reports, which LivaNova uses to announce items such as quarterly financial results, business update conference calls, and board appointments. For example, the company has filed 8‑K reports to furnish press releases on results for quarters ended June 30 and September 30, and to disclose the appointment of a new director to its Board and Audit and Compliance Committee.
Investors and analysts can also use this page to locate LivaNova’s annual and periodic reports, which typically include information on its Epilepsy and Cardiopulmonary businesses, neuromodulation therapies such as VNS Therapy, and its global operations in neurological and cardiac conditions. These documents can help readers understand segment performance, risk factors, and other disclosures that complement the company’s press releases.
Stock Titan enhances these filings with AI‑powered summaries that explain the key points of lengthy documents, such as earnings releases or other detailed reports. Real‑time updates from the EDGAR system ensure that new LivaNova filings appear promptly, while AI highlights important sections so users can quickly see what changed, which items are being furnished rather than filed, and how corporate events may relate to LIVN stock.
Users interested in governance and oversight can review filings that describe board composition and committee membership. Those focused on financial performance can concentrate on filings that furnish earnings press releases and related metrics.
LivaNova PLC (LIVN) Q2-25 10-Q highlights:
- Net revenue rose 10.6% YoY to $352.5 m; six-month revenue up 9.1% to $669.4 m.
- Gross margin held steady at 67.8%; operating income jumped 34.9% to $54.2 m on disciplined SG&A (+10.1%) and R&D spend (-7.9%).
- GAAP EPS improved to $0.50 versus $0.30; diluted share count 54.7 m.
- Six-month results swung to a $300.2 m loss after booking a $362.1 m SNIA environmental charge.
- Cash climbed to $593.6 m (-$130 m q-o-q after releasing $294.7 m restricted cash); total debt reduced 31% to $430.6 m following a $200 m early term-loan repayment.
- SNIA litigation reserve now $392.3 m; €270 m surety bond in place pending appeal. Cyber-incident costs reached $13 m, with $9.6 m insurance recovery to date.
- Liquidity: $225 m revolver undrawn; operating cash flow +63% YoY to $86.9 m H1-25.
- No covenant breaches; capped-call and embedded derivatives re-measured, neutral P&L effect.
Management reaffirmed focus on core Cardiopulmonary & Neuromodulation segments and continues restructuring begun 2024. Litigation and environmental exposures remain the key overhang despite solid operating momentum and deleveraging.